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1Centre for Altitude Space and Extreme Environment Medicine, Portex Unit, UCL Institute of Child Health, 30 Guilford Street, London,
WC1N 1EH, UK, 2Warwick Medical School, Division of Metabolic and Vascular Health, University of Warwick, Gibbet Hill Road,
Coventry CV4 7AL, UK, 3Department of Translational Physiology, Academic Medical Center, 1105 AZ Amsterdam,
The Netherlands, 4Human Bio-Energetics Research Centre, Crickhowell, Powys, NP8 1AT, UK.
Lowland residents adapt to the reduced oxygen availability at high altitude through a process known as
acclimatisation, but the molecular changes underpinning these functional alterations are not well
understood. Using an integrated biochemical/whole-body physiology approach we here show that plasma
biomarkers of NO production (nitrite, nitrate) and activity (cGMP) are elevated on acclimatisation to high
altitude while S-nitrosothiols are initially consumed, suggesting multiple nitrogen oxides contribute to
improve hypoxia tolerance by enhancing NO availability. Unexpectedly, oxygen cost of exercise and
mechanical efficiency remain unchanged with ascent while microvascular blood flow correlates inversely
with nitrite. Our results suggest that NO is an integral part of the human physiological response to hypoxia.
These findings may be of relevance not only to healthy subjects exposed to high altitude but also to patients
in whom oxygen availability is limited through disease affecting the heart, lung or vasculature, and to the
field of developmental biology.
B
arometric pressure falls with increasing altitude whilst the percentage of oxygen within the atmosphere
remains constant. The consequent reduction in inspired oxygen impairs physical performance and may
even threaten survival.1 Graded and continued altitude exposure permits acclimatisation, a progressive
tolerance to hypoxia traditionally ascribed to cardiopulmonary and haematological responses that support global
convective oxygen delivery.2 However, such responses do not provide a full explanation of the acclimatisation
process given that exercise tolerance remains limited even though arterial oxygen content returns to sea-level
values.3,4 Furthermore, genetic selection pressure amongst high-altitude residents of the Tibetan Plateau (in situ
for.20,000 years) favours lower rather than higher levels of oxygen-carrying haemoglobin.5,6 Finally, themarked
inter-individual differences which exist in the ability to adapt to hypoxia are not explained by differences in
arterial oxygen content.3 Changes in tissue oxygen handling, mediated in part through changes in the micro-
circulation and in mitochondrial oxygen use, are increasingly considered more important to the development of
hypoxia tolerance than is the augmentation of its global convective delivery.7–9 If acclimatisation is in part
dependent upon these mechanisms, how might this occur?
Nitric oxide (NO) is a ubiquitous signalling molecule produced through themetabolism of L-arginine by nitric
oxide synthases (NOS). Its formation is crucial for the control of blood pressure, blood flow, and other vital bodily
functions.10 Amongst these, it is an important antioxidant,11 and a regulator of intermediary metabolism12 and
cellular energy production by mitochondria.13 NO availability may be reduced at altitude since i) its enzymatic
production depends on the availability of oxygen and ii) exposure to hypoxia results in a paradoxical increase in
the production of reactive oxygen species (in particular when combined with physical activity)14 leading to NO
inactivation. This is consistent with the notion that hypoxia leads to an increase in the expression of different NOS
isoforms via upregulation of HIF-1a, a master transcriptional regulator of oxygen homeostasis. However, the
situation is complex inasmuch as HIF-1a stability is controlled not only by the availability of oxygen but also that
of NO.15 Moreover, recent studies suggest an alternative pathway of NO generation16 that involves sequential
reduction of nitrate (NO32) to nitrite (NO22) and further to NO, and which is inhibited by oxygen.17 Perhaps for
these reasons, Tibetan highlanders exhibit elevated levels of circulating NO products (including plasma nitrate
and nitrite) when compared to lowlanders. The combination of high NO production and low haemoglobin
concentration in this population is associated with increased forearm blood flow.18 Intriguingly, lowlanders
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adapting to high altitude exhibit reduced blood flow in the micro-
circulation (arterioles, capillaries, and venules less than 100 mm in
diameter).19Whether or not this phenomenon ismodulated by endo-
genous NO or its metabolites is unknown. Recent reports of reduced
oxygen cost of exercise and improved mitochondrial efficiency fol-
lowing dietary nitrate supplementation at sea-level20,21 support the
notion that high nitrite/nitrate levels in Tibetans might be associated
with beneficial metabolic adaptation to hypoxia. Thus, enhanced NO
production may not be unique to highlanders but part of the integral
human physiological response to hypoxia.We hypothesized that NO
availability would be increased in lowland residents acclimatizing to
altitude and that this would be associated with (i) reduced oxygen
cost and improved efficiency of oxygen utilization during exercise
and (ii) increased microcirculatory blood flow.9
Results
Basic physiological changes on ascent to Everest Base Camp.
Incremental exposure of healthy lowlanders to profound hypoxia
at high altitude was accompanied by a progressive increase in
respiratory rate (particularly upon exercise), heart rate and blood
pressure (Fig. 1a), the expected cardiopulmonary adjustments
to the unavoidable reduction in oxygen availability. Unchanged
plasma osmolality (Fig. 1b) indicates that individuals remained well
hydrated. Furthermore, unchanged plasma protein and creatinine
concentrations provide no evidence of protein catabolism or
renal dysfunction. Differences in circulating biomarker levels,
therefore, reflect true concentration changes rather than body
fluid shifts. Average body weight changes remained below 5% at
all altitudes. Unchanged plasma levels of the (pro)inflammatory
cytokines IL-6 and TNF-a document the absence of acute inflam-
mation (Fig. 1b).
Oxygen saturation of arterial haemoglobin decreased with ascent
due to the reduction in inspired oxygen partial pressure (Fig. 1c).
Consequently, haemoglobin concentration increased under the
influence of elevated erythropoietin such that oxygen content was
maintained at sea-level values at all altitudes. Despite this, oxygen
consumption at the lactate threshold and at VO2peak decreased with
ascent, with peak oxygen consumption falling by 35% at 5,300m
(Fig. 1d).
Figure 1 | Ascent Profile and Altitude-Related Effects on the Cardio-Pulmonary System as well as the Delivery and Consumption of Oxygen During
the 2007 Caudwell Xtreme Everest Expedition. (a) Arrows in top chart indicate location and timing of exercise testing and blood sampling. Breathing
frequency and heart rate before and after a standardized 2-min step exercise protocol and resting blood pressure were recorded daily for all members of the
Core Team (seeMethods for details). (b) Changes in haematocrit, plasma osmolality and protein concentration were quantified together with circulating
levels of interleukin-6 (IL-6) tumor necrosis factor alpha (TNF-a), creatinine and erythropoietin (EPO). (c) Variables affecting oxygen delivery included
partial pressure of oxygen (black bars), arterial oxygen saturation at rest (dark grey bars), haemoglobin concentration (light grey bars), and arterial oxygen
content (open bars). (d) Effects of hypoxia on exercise performance, expressed as rates of oxygen consumption at the lactate threshold (LaT) and at
maximal work rate (VO2max). Results are means 6 SEM; n524.
www.nature.com/scientificreports
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Ascent to high altitude is accompanied by increased oxidative
stress. Altitude acclimatisation was accompanied by elevation
in the levels of three independent indices of oxidative stress:
increased concentrations of (i) 8-iso-prostaglandin F2a (F2-isopros-
tane, a lipid oxidation product and potential disease mediator fre-
quently used in translational studies) and (ii) 4-hydroxy-2-nonenal
(HNE, a lipid peroxidation product known to form stable adducts
with cysteine and histidine residues in proteins and to play a role in
cell signalling), and (iii) a decrease in the ratio of reduced/oxidized
glutathione, the most abundant low-molecular weight antioxidant
(Fig. 2a). While the biological sources of the lipid oxidation products
and the main site(s) of glutathione oxidation remain unclear and
changes in these plasma indices peak at different altitudes (presum-
ably due to variations in chemical reactivity and pathways of
formation), a consistent elevation of all three biomarkers compared
to sea-level values indicates sustained oxidative stress. In the absence
of a compensatory increase in NO production, such changes
would be expected to result in enhanced inactivation of NO by
superoxide22 and perhaps other reactive oxygen species, causing
reduced NO availability and consequently impaired local NO-
cGMP signalling.
Production and availability of nitric oxide are enhanced during
ascent to high altitude.NO formation and availability were assessed
by quantification of the oxidative decomposition products, nitrite
and nitrate, the second messenger cyclic 3’,5’-guanosine monopho-
sphate (cGMP), and protein nitrosation products in plasma. Plasma
nitrate and nitrite levels were increased at all altitudes above 1,300m,
indicative of elevatedNOproduction, withmaximal levels at 3,500m,
following the greatest rate of altitude gain (Fig. 2b). Elevation of
cGMP, in the context of minimal fluctuations in plasma natriuretic
peptide (ANP, BNP, CNP) levels (an alternative pathway through
which cGMP could be enhanced), indicates increased NO availabi-
lity. Cyclic GMP was elevated at all altitudes above sea level,
also peaking at 3,500m. In contrast, protein nitrosation products,
approximately half of which corresponded to S-nitrosothiols
(RSNOs), dropped by.50% upon arrival at 1,300m and then gradu-
ally rose to reach sea-level values one week after arrival at 5,300m.
Surprisingly, cGMP levels did not correlate with NO metabolite
concentrations, suggesting that multiple pathways modulated NO
availability. For example, elevated cGMP at 1,300m, in the face of
negligible changes in nitrite and nitrate and markedly reduced
plasma nitrosothiols, suggests utilization of S-nitrosoalbumin as a
Figure 2 | Ascent to Everest Base Camp is Associated with Increased Oxidative Stress as well as Enhanced Formation and Availability of Nitric Oxide.
(a) Effects of hypoxia on oxidative stress biomarkers are expressed as differences in plasma concentration of 8-iso-prostaglandin-F2a (8-iso-PGF;
F2-isoprostanes), 4-hydroxy-2-nonenal (HNE), and the ratio of reduced to oxidized glutathione (GSH/GSSG) at the indicated altitudes from normoxic
concentrations at sea level (75 m, London, UK); (b) Circulating concentrations of the nitric oxide relatedmetabolites, nitrite (NO2
2) and nitrate (NO3
2)
as well as the second messenger cyclic guanosine 3’, 5’-monophosphate (cGMP) are elevated in hypoxia while plasma S-nitrosothiols (RSNOs)
experienced a dramatic drop compared to sea level conditions on arrival at Kathmandu (1,300 m) before progressively increasing. In contrast, pro atrial
natriuretic peptide (proANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) variations are minimal. Plasma concentrations at
each altitude correspond to time of exercise testing;means6 SEM (n524). (c) Correlations betweenNOmetabolites and variables of oxygen delivery and
consumption at sea level (all variables log-transformed).
www.nature.com/scientificreports
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source of NO during (passive) exposure to hypobaric hypoxia during
the flight from London to Kathmandu. Moreover, higher nitrite and
nitrate concentrations were associated with greater resting oxygen
consumption at sea level. However, only nitrate was inversely related
to haemoglobin concentration and blood oxygen content while the
opposite was true for nitrosothiols (Fig. 2c), suggesting a complex
interplay of bioactive NO metabolites affecting oxygen delivery and
consumption. Several of these associations dynamically changed
during ascent to high altitude. For example, while the correlation
between cGMP and resting oxygen saturation gradually increases
in slope the positive association of nitrite with oxygen consumption
inverts on ascent (Fig. 3a). The latter suggests enhanced extraction of
nitrite from the circulation as hypoxia increases.
Changes in oxygen cost of exercise and microvascular blood flow
during ascent.Unexpectedly, the oxygen cost of steady-state exercise
(defined as the increase in oxygen consumption per unit increase
in work rate in ml O2/min/watt20) was unchanged at altitude.
Furthermore, mechanical efficiency expressed as delta efficiency
(sea-level: 27.3% (3.0); 5,300m 26.8% (3.2), mean (sd)) and net effi-
ciency (sea-level: 22.3% (1.8); 5,300m 23.3% (3.1)) remained
unchanged. Again, complex altitude-dependent patterns of associa-
tions were observed between NOmetabolites and net efficiency dur-
ing ascent (Fig. 3a).
As previously reported,19 microvascular blood flow in small
(,25 mm diameter) and medium-sized (26–50 mm) vessels is
reduced with ascent. Unexpectedly, blood flow in the microcircula-
tion was consistently and inversely correlated with nitrite levels at
3,500m and 5,300m but positively correlated with cGMP at 5,300m
(Fig. 3b), consistent with a role for cGMP in blood flow regulation.
Phenotypical differences are apparent already at moderate alti-
tudes. Intriguingly, subgroup analyses comparing the fourteen
members of the climbing team (all of whom had significant previous
extreme-altitude experience and later ascended above 5,300m9) with
the ten base-camp laboratory staff (with less previous altitude expo-
sure andwho remained at 5,300m for the duration of the expedition9)
revealed higher erythropoietin, nitrate and cGMP levels in the clim-
bers (Fig. 3c). Although not statistically significant, these differences
are indicative of higher NOS activity in climbers, apparent already at
moderate altitude (3,500m), and may represent evidence of self-
selection for higher NO production or epigenetic imprinting from
previous altitude exposure.
Discussion
Using an integrated multi-biomarker/whole-body physiology
approach in humans, we here demonstrate that NO formation
Figure 3 | Altitude Dependent Associations between Plasma NOMetabolites, VO2peak and Net Efficiency, Relationship between Plasma Nitrite and
Microvascular Blood Flow, and Sub-group Analyses. (a) Directional change in associations between peak oxygen consumption (VO2peak) and plasma
nitrite at different altitudes (log-transformed values) along with an association matrix of altitude-dependent changes in NO metabolites with net
efficiency at 40W. (b) Correlations betweenmicrovascular blood flow in small andmedium-sized vessels and plasma nitrite as well as cyclic guanosine 3’,
5’-monophosphate (cGMP; insets) concentrations. (c) Subgroup analyses for nitrate, cGMP and erythropoietin (EPO) levels in lab staff (n510) and
climbers (n514); means 6 SEM.
www.nature.com/scientificreports
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increases in lowlanders ascending to high altitude, in agreement with
a role in adaptation to hypoxia. Our findings are consistent with
earlier observations of elevated NO metabolite concentrations in
the blood of Tibetan highlanders18 and show that enhanced NO
production is not unique to this particular population (perhaps as
a result of evolutionary selection pressure over millennia) but an
integral physiological response to hypoxic stress in humans. In spite
of a parallel increase in oxidative stress with hypoxia, in well accli-
matised lowlanders not only the production but also the availability
of NO is enhanced at all altitudes. Furthermore, we show that
enhanced NO levels are associated with changes in microcirculatory
blood flow whichmay affect local tissue oxygen delivery. Contrary to
our expectations, we found no evidence for a change in the oxygen
cost of exercise. Unchanged oxygen cost with physiological elevation
of nitrite in lowlanders at altitude contrasts with reduced oxygen cost
of work shown in studies of dietary nitrate supplementation at sea
level20,21 and in Tibetans at altitude.23 However, nitrite levels in
Tibetan highlanders exceed those observed in our subjects by an
order of magnitude,18 raising the possibility that improved mech-
anical efficiency may have evolved as an adaptation to residence in
a hypoxic environment in this population.
In many cases, the biochemical changes in response to high alti-
tude exposure are so striking that almost everything is statistically
significant when compared to baseline. However, uncovering
the biological relevance of those alterations remains a challenge.
Relatively small (and statistically insignificant) changes in the
steady-state concentration of biomarkers and signalling molecules
may be associated with biologically significant changes in physiology,
in particular when regulatory circuits are operating at their limits. In
other cases, statistically significant changes frombaselinemay simply
indicate that the system is operating at a different setpoint (which
may still be well within the regulatory range). Given the significance
of NO in the regulation of so many vital bodily functions, including
vascular tone and mitochondrial activity, an enhanced NO availabi-
lity would seem to be important for sustained local NO signalling
under conditions of globally elevated reactive oxygen species pro-
duction, as we here document to occur on sojourn to high altitude.
This seems to be accomplished by a combination of factors, including
elevated de novo synthesis by NOS (resulting in higher levels of
circulating nitrite and nitrate), release of NO by redox-activation
of plasmatic storage forms (as evidenced by the initial drop in
S-nitroso species), and reduction of nitrite (indicated by gradual
directional changes in association between plasma nitrite concentra-
tions and some of the physiological parameters on exposure to
increasing levels of hypoxia). Reduction of nitrite (and possibly also
nitrate)16 may also account for our observation that peak nitrite and
nitrate levels were not sustained on prolonged stay at high altitude; in
addition, it may have limited the magnitude of the increases mea-
sured. That elevated NO production indeed translates into enhanced
NO bioavailability (in spite of concomitantly elevated reactive oxy-
gen species production) is suggested by the increases in circulating
cGMP concentrations we detected at high altitude; in the absence of
major changes in natriuretic peptide levels, which could also have
contributed to those changes via stimulation of particulate guanylyl
cyclase, and no reason to suspect an inhibition of phosphodiesterase
activity24, this signature is consistent with an enhanced NO activity.
Although elevations in circulating cGMP levels appear to be rather
robust this does not necessarily translate into increases in blood flow,
a prerequisite for enhanced convective delivery of oxygen through
the blood. This conclusion is supported by the contrasting associa-
tions of microvascular blood flow with circulating nitrite and cGMP
levels. Pharmacological doses of nitrite can lower blood pressure,25,26
but whether or not this extends all the way down to physiological
levels is currently unknown. Our observation that physiological
nitrite concentrations, at sea level and across altitudes, are negatively
correlated with blood flow in the microcirculation was unexpected
but is consistent with (i) its lack of direct vasodilator activity at
low-to-moderate concentrations27 and (ii) the increase in blood pres-
sure at low nitrite doses observed in animals28 and humans.29 Thus,
while the positive correlation of microvascular blood flow with
cGMP at 5,300m suggests that NO formation (from NOS or nitrite
reduction) is enhanced, this appears to be insufficient to normalize
reducedmicrocirculatory blood velocity. An alternative or additional
explanation, given that all metabolites were measured in venous
plasma, is that nitrite present in arterial blood was metabolized to
NO in upstream capillary beds and that the cGMP and blood flow
changes are reflections of that process. Paradoxically, if diffusion
limitation of oxygen is a critical factor with respect to performance,
slower blood flow at high altitude19 may be a beneficial adaptation
allowing increased time for oxygen unloading in tissues. Alterations
in microcirculatory function have been associated with morbidity
and mortality in human sepsis.30 It would seem to be important,
therefore, to clarify whether these alterations are indeed unfavour-
able perturbations of normal physiology or perhaps an intentional
feature in tissue hypoxemia, and whether or not therapeutic
enhancement of microvascular blood flow under these conditions
has merit.
Although our results suggest that several different pathways and
sources of NO cooperate to enhance NO availability in response
to hypoxia, the precise mechanisms that confer enhanced hypoxia
tolerance remain unclear. Our study is limited inasmuch as it does
not provide information about accompanying changes in NO meta-
bolite levels in vascular tissue, skeletal muscle, or red blood cells,
compartments also expected to contribute to the physiological adap-
tations observed. Moreover, it remains unclear at this stage whether
NO itself or a change in NO-related post-translational modification
(such as S-nitrosation) of proteins or transcription factors, or all of
the above, contribute(s) to beneficial adaptation to hypoxia. Of note,
S-nitrosothiols transduce the ventilatory response to hypoxia31 and
HIF-1a itself is a target for S-nitrosation.32 Thus, nitrosothiols may
not only act as sources of NO (as indicated by the initial drop in
S-nitrosoalbumin in the present study) but also as signal trans-
ducers,33 and changes in S-nitrosation status may affect many other
downstream processes. Although themain objective of our study was
to assess the temporal and quantitative changes of theNOpathway in
adaptation to hypoxia during ascent to high altitude several intri-
guing associations between biochemical parameters and physio-
logical variables (e.g., NO production with oxygen consumption at
rest, S-nitrosothiols with blood oxygen content, and the inverse rela-
tionship between nitrate and haemoglobin) at sea-level are worthy of
further investigation. Clearly, additional mechanistic investigations
are warranted to identify the sources of NO and reactive oxygen
species production (i.e. whether they originate in blood cells, vascular
tissue, and skeletal muscle or are derived from other organs), the
sequence of signalling pathways involved, and their relationship
with tissue phenotypic changes (e.g. microcirculatory blood flow).
Nevertheless, our results suggest that the observed changes in micro-
vascular function are likely to involve cGMP-independent effects13
mediated by longer-lived NO metabolites such as nitrosothiols,
nitrite and nitrate. Considering the rich chemical biology of NO in
relation to its reaction with oxygen and reactive oxygen species34 it is
likely that in addition to HIF-1a several other redox-sensitive sig-
nalling nodes are involved in the acclimatisation process.
Our findings may be of relevance not only to healthy subjects
exposed to hypobaric hypoxia, but also to patients in whom oxygen
delivery is limited through disease affecting the heart, lung or vascu-
lature,8 and to the field of developmental biology.35 Cellular hypoxia
with consecutive organ dysfunction/damage is a near universal
problem in critical illness. Patient management decisions with large
resource implications are often based on very limited ‘hard data’, and
few biomarkers other than indices of inflammation or acute tissue
damage are available to guide this process. Cellular hypoxia may
www.nature.com/scientificreports
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result from anemia, from pulmonary, cardiac micro-and macrovas-
cular pathology, or from abnormal oxygen handling. Whilst tol-
erance to hypoxia has traditionally been considered to depend on
increased convective delivery, efforts to maximize oxygen supply or
utilization either provide no benefit or are harmful.36,37 Mechanisms
underpinning inter-individual differences in the ability to cope with
hypoxia in human (patho)physiology, which ultimately translate
into differences in outcome, are largely unexplored - in part because
the complex (often multi-system) nature of critical illness represents
a major obstacle to mechanistic investigation. The search for pro-
gnostic markers in critical illness is particularly challenging due to
themultitude of derangements in signalling/metabolic pathways that
characterize conditions involving multiple organ failure. Moreover,
many of the classical markers are affected by the often aggressive
treatment and invasive procedures applied, posing a challenge to
untangling cause/effect relationships. An alternative approachmight
begin with the detailed study of healthy individuals exposed to pro-
found and prolonged hypoxia, where functional heterogeneity can be
linked to biological diversity by use of an integrated biochemical/
whole-body physiology assessment, and translation through applica-
tion of derived data to the patient population. Thus, systematic
identification and study of the molecular signatures of pathways
involved in hypoxic adaptation in healthy individuals may hold the
key to understanding adaptation to reduced oxygen availability in
critically ill patients, and help identify novel therapeutic targets. In
this regard, our data suggest that individuals unable to mount an
adequate intrinsic response to hypoxia may benefit from direct
(nitrite, nitrate) or indirect (e.g., small-molecule modulators of
NOS expression/activity) manipulation of NO metabolism to activ-
ate the physiological program that confers tolerance to hypoxia. The
results of the current study alsomake us wonder whether the findings
of greater mortality in septic shock patients treated with a NOS
inhibitor a decade ago38 might now perhaps be interpreted as
proof-of-concept that survival in stress/hypoxia depends on a suf-
ficient production of NO. Finally, our study raises the intriguing
possibility that maximizing arterial oxygen levels (PaO2) in patients
who have been exposed to sustained hypoxia may be harmful, if
cellular energetics and organ function have become reliant on
reductive rather than oxidative pathways of NO generation. This
may be particularly pertinent to the neonatal intensive care setting
where, after months of embryonic development under conditions
of physiological hypoxia, our youngest patients are likely to suffer
disproportionately from additional oxidative damage due to a low-
capacity anti-oxidative defence system.
Methods
This study was approved by the University College London Research Ethics
Committee, in accordance with the Declaration of Helsinki. Verbal and written
informed consent was obtained from all subjects.
Expedition setting and ascent profiles.Twenty four healthy subjects (18male; mean
age 35.2 years; age range 19–59 years)who were investigators on the Caudwell Xtreme
Everest 2007 research expedition to Mount Everest participated in this study. The
design and conduct of this study is described in detail elsewhere.9 All subjects were
free of cardiovascular or respiratory disease and took no medication. Subjects were
sea level natives who had been resident at sea level for a minimum of 3 months and
had not participated in any form of hypoxic training prior to departure for the
expedition. The subjects underwent baseline testing in London (altitude 75 m;
barometric pressure 754mmHg, 100kPa) before travelling by plane to Kathmandu,
Nepal (1,300 m; 650mmHg, 86.7kPa; PiO2 650mmHg, 86.7kPa). From there they
flew to Lukla (2,800 m, expedition day 1) and then trekked to Everest Base Camp
(EBC; 5,300 m, 404mmHg, 53.8KPa; PiO2 74.7 mmHg, 9.9 kPa), arriving on
expedition day 13. The ascent profile is detailed in Fig. 1a. Testing was repeated
during the ascent in field laboratories in Kathmandu (1,300 m; day23 to 0), Namche
(3,500 m; day 4 to 6), Pheriche (4,250 m; day 9 to 10), and at EBC (5,300 m; day 15 to
17), with ambient temperatures well controlled during testing. All subjects followed
an identical ascent profile during the ascent to EBC and, to standardize hypoxic
exposure, were prevented from excursions of more than 300 m from the group
altitude at any time. The subjects were divided into two subgroups, Group 1 (labor-
atory staff) who subsequently remained at EBC for the duration of the expedition
(n510) andGroup 2 (climbers; n514) who subsequently ascended above 5,300 m, to
a maximum of 8,848 m on Mount Everest. Criteria for participation in the climbing
team were previous extreme altitude experience (event-free ascents over 6,500 m),
general mountaineering experience (assessed by the expedition leader and climbing
leader) and a demonstrated ability to conduct medical research at high altitude. An
additional criterion for summit climbers was a previous successful event-free ascent
over 8,000 m.
Basic physiological measurements and peripheral oxygen saturation. All subjects
completed a physiological and symptom scoring diary for each day of the expedition.
The basic physiological profile included resting heart rate, blood pressure (BP),
respiratory rate and peripheral arterial oxygen saturation (SpO2), repeated (with the
exception of BP) after a standardized 2-min step exercise challenge (CXE step test:
20 cm step, firm base, alternate feet sequentially, 1 step up or down s21 by electronic
metronome). SpO2 was measured using a pulse oximeter (Onyx 9500, Nonin, USA).
This device has been previously validated at moderate altitude (maximum of 2,250m)
and in acute hypoxia to an SpO2 of approximately 70%; all measurements were taken
from the right index finger. The value displayed in the last 10 s of a continuous one
minute measurement period at rest was recorded. Data collection for the diary study
was completed shortly after waking eachmorning, before the ingestion of any food or
caffeine containing beverages. All subjects rested in a sitting position for a minimum
of 5 min prior to recording resting measurements, and subjects were blinded to their
own measurements to prevent voluntary manipulation of respiratory patterns.
Cardiopulmonary exercise testing and oxygen consumption measurements.
Incremental exercise testing to exhaustion was performed to identify the lactate
threshold (anaerobic threshold or gas exchange threshold39,40) and peak oxygen
consumption (VO2peak). Subjects fasted for 3 hrs prior to the exercise test and
refrained from caffeine on the day of testing. The subjects performed an incremental
ramp test to the limit of tolerance using an electromagnetically braked cycle
ergometer (Lode Corival, Lode, Groningen, TheNetherlands) and a breath-by-breath
cardiopulmonary exercise testing system (CPET) (Metamax 3b, Cortex, Leipzig,
Germany). A ramp slope of 20–35 W/minute was chosen depending on the sex, age
and physical fitness of the subjects in order to obtain a test duration of approximately
10–15 min.41 This was kept constant at all altitudes. Resting measurements were
recorded for 3 min, followed by 3 min of unloaded cycling followed by initiation of
the incremental ramp.42 The limit of tolerance (maximum)was defined as the point at
which the subject could not maintain a pedalling cadence of 60 rpm despite
encouragement.
A full calibration of the breath-by-breath system was performed before each test
using precision gas mixtures (BOC, Guildford UK) (21% oxygen, 0.03% carbon
dioxide and 15% oxygen/5% carbon dioxide). The validity of the CPET device was
confirmed with a metabolic calibrator (Vacumed, CA) prior to testing in London and
in the laboratory in Nepal.43 The accuracy and reliability of the Metamax 3B gas
analyzers and flowmeter were established in a hypobaric chamber (RAF Hendon,
UK) prior to departure and were demonstrated to correspond to the specifications
defined in the American Thoracic Society guidelines.44 The ergometer was calibrated
with a torque-based mechanical ergometer calibrator (Vacumed, CA) prior to testing
in London and in the laboratory at EBC. Accuracy and reliability of the ergometer
were also established in a hypobaric chamber prior to departure. The gas exchange at
the lactate threshold was identified firstly using the V-slope method and confirmed
using the ventilatory equivalents method. The methods previously described by
Whipp et al. were used to identify these points.39 Peak oxygen consumption
(VO2peak) was calculated as the average oxygen consumption rate for the individual
breaths taken in the final 20 s of the exercise test.
To determine the oxygen cost of moderate intensity exercise and mechanical
efficiency, subjects performed three 10 minute constant work rate tests (CWR) below
the lactate threshold. The mean oxygen consumption was calculated from the last
5 minutes of each work rate after steady-state had been established. Mechanical
efficiency was expressed as delta efficiency (the ratio of the change in energy
expenditure to the change in external work) and net efficiency (the ratio of total
oxygen consumption less resting oxygen consumption to external work).
Microcirculation assessment. The sublingual microcirculation was visualized at rest
by means of sidestream dark-field imaging using the Microscan SDF camera
(Microvision Medical, Amsterdam, The Netherlands).19 All images were obtained by
a single investigator experienced in this technique. Subjects were required to rest for
10 minutes with a closed mouth prior to the investigation. Microvascular blood flow
was assessed using the microcirculatory flow index. Two experienced investigators
independently assessed each film to generate an MFI score according to published
guidelines.45
Blood sampling and determination of haemoglobin concentration. All blood
samples were taken prior to exercise testing and drawn from the antecubital vein into
EDTA containers (BDVacutainer). Haemoglobin (Hb) concentrations in blood were
determined immediately after sampling using a handheld photometric device
(HemocueH Whole Blood Haemoglobin System, HemoCue AB, Angelhoim,
Sweden), which has been shown tomeasure venous Hb concentration as accurately as
an automated spectrophotometer. Measurement ‘cuvettes’ for the Hemocue were
stored according to manufacturer’s recommendations within a thermostatically
controlled storage unit for the duration of the expedition.
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Calculation of arterial oxygen content. Arterial oxygen content (CaO2) was
calculated as the product of Hb concentration, SpO2 and Hufner’s constant
[CaO2 5 (SaO2 3 Hb 3 1.39)]. This formula calculates the proportion of oxygen
bound to Hb within red blood cells but does not account for dissolved oxygen in
plasma. As the latter normally corresponds to ,2% of total oxygen carriage in the
blood it was considered a reasonable estimation of arterial oxygen content under the
study conditions.
Plasma biomarker analyses. Venesection was performed for the measurement of
circulating biomarkers. Plasma was separated from blood cells by centrifugation of
whole blood at 800xg for 15 min and immediately frozen in 1 ml aliquots in liquid
nitrogen. Samples were stored for the duration of the expedition including their
transport back to Kathmandu at liquid nitrogen temperatures. They were then
transported back to the UK on dry ice and kept at240uC in a commercial cryostorage
facility until analysis.
Oxidative stress markers were analyzed in duplicate directly from EDTA plasma.
Isoprostanes (8-iso-prostaglandin F2a) and 4-hydroxy-2-nonenal (HNE) were
quantified using direct competitive enzyme immunoassay (Assay Designs, Ann
Arbor, MI) and ELISA (OxiSelect HNE-HIS Adduct ELISA kit, Cell Biolabs, San
Diego, CA), respectively. Reduced and oxidized glutathione were determined spec-
trofluorimetrically (DetectX, Arbor Assays, AnnArbor,MI). Concentrations of cyclic
GMP and natriuretic peptides were determined by commercial immunoassay kits
(R&D Systems, Abingdon, UK; Biomedica, Vienna, Austria).
NOmetabolite concentrations were quantified immediately after thawing of frozen
plasma aliquots in the presence of an excess of N-ethylmaleimide (NEM, in PBS;
10 mM final concentration). For the analysis of circulating S-nitrosothiol concen-
trations aliquots ofNEM-treated EDTAplasmawere directly injected into a triiodide-
containing reaction chamber, and the NO produced from the reduction of protein
nitroso species was quantified by gas phase chemiluminescence (CLD 77sp,
EcoMedics), as described.46 The concentration of S-nitrosothiols in these samples was
estimated from the difference in NO signal before and after sample pre-treatment
with mercuric chloride. For nitrite/nitrate analysis, NEM-treated samples were
deproteinized with ice-cold methanol (151 v/v), cleared by centrifugation and sub-
jected to analysis by high pressure liquid chromatography using a dedicated nitrite/
nitrate analyzer (ENO20, Eicom). Sample processing was performed in a staggered
fashion to ensure reproducible processing times. All determinations were carried out
in duplicate, with repeated daily calibrations, and reported values are corrected for
background contaminant levels of nitrite/nitrate.
Erythropoietin was quantified by ELISA (Bender MedSystems, Vienna, Austria),
and interleukin-6 and TNF-a using XMAP technology (BioPlex 200, Luminex/
BioRad). Plasma creatinine and protein concentrations were determined by the Jaffe
and Bradford reactions, respectively, and plasma osmolality using a micro-osmo-
meter (Model 3320, Advanced Instruments).
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